Ovarian cancer is a devastating malignancy since in many cases women are first diagnosed after the disease has already spread, or metastasized. Even after aggressive surgery and combination cytotoxic chemotherapy, very often this relentless disease returns quickly with evolved chemotherapy-resistance. Therefore, the overarching theme of the Shepherd lab, within the Translational Ovarian Cancer Research Unit (TOCRU), is to elucidate the molecular and cellular mechanisms involved in ovarian cancer metastasis and test new therapeutic strategies to target and alleviate late-stage disease and chemo-resistance.The TOCRU represents fundamental and translational research activities co-led by scientists Drs. Shepherd and Gabriel DiMattia, and in close collaboration with gynaecologic oncology surgeons and other members of the Gynaecologic Oncology Multidisciplinary Disease Site Team at the London Regional Cancer Program. Together, the TOCRU team has made significant discoveries through the novel development and use of ovarian cancer patient ascites-derived cell lines representing disease diversity and their application of an in vitro three-dimensional spheroid culture model of metastasis and tumour biology. The continued objective of the TOCRU is to ultimately apply new research discoveries to impact the lives of ovarian cancer patients with improved therapies to prolong disease-free survival and improve overall quality-of-life.